Docetaxel in Node Positive Adjuvant Breast Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

1,491

Participants

Timeline

Start Date

June 30, 1997

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions
Breast Cancer
Interventions
DRUG

Docetaxel

intravenous

DRUG

5-fluorouracil

intravenous

DRUG

Doxorubicin

intravenous

DRUG

Cyclophosphamide

intravenous

Trial Locations (20)

08807

Sanofi-Aventis Administrative Office, Bridgewater

Unknown

Sanofi-Aventis Administrative Office, Buenos Aires

Sanofi-Aventis Administrative Office, Vienna

Sanofi-Aventis Administrative Office, São Paulo

Sanofi-Aventis Administrative Office, Laval

Sanofi-Aventis Administrative Office, Prague

Sanofi-Aventis Administrative Office, Cairo

Sanofi-Aventis Administrative Office, Paris

Sanofi-Aventis Administrative Office, Berlin

Sanofi-Aventis Administrative Office, Athens

Sanofi-Aventis Administrative Office, Budapest

sanofi-aventis Administrative office, Netanya

Sanofi-Aventis Administrative Office, Warsaw

Sanofi-Aventis Administrative Office, Porto Salvo

Sanofi-Aventis Administrative Office, Bratislava

Sanofi-Aventis Administrative Office, Midrand

Sanofi-Aventis Administrative Office, Barcelona

Sanofi-Aventis Administrative Office, Bromma

Sanofi-aventis adminsitrative office, Guildford Surrey

Sanofi-aventis administrative office, Montevideo

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Cancer International Research Group (CIRG)

OTHER

lead

Sanofi

INDUSTRY